Biotech News

by Jacob Bell on 21 Febbraio, 2020 at 10:45 pm

Following an FDA approval Friday, Esperion intends to sell bempedoic acid under the brand name Nexletol for a price of about $10 per day.

by Jacob Bell on 21 Febbraio, 2020 at 5:15 pm

A decision by the FDA on whether to approve valrox, potentially the first gene therapy for hemophilia, should come by late August. 

by Jacob Bell on 21 Febbraio, 2020 at 5:05 pm

Thursday's update is the second time results from a large study of the French drugmaker's main drug, called elafibranor, have been pushed back.

by Ned Pagliarulo on 21 Febbraio, 2020 at 5:00 pm

Bringing the facility in Durham, North Carolina, online is a critical step for the Swiss pharma's plans to expand the market for Zolgensma, its gene therapy for spinal muscular atrophy.

by Nick Paul on 21 Febbraio, 2020 at 12:42 pm

Siegfried Reich has ended his seven-year involvement with Effector Therapeutics. Reich co-founded Effector and served as its senior vice president of research but has moved on to take up the chief scientific officer position at Turning Point Therapeutics.

by Ben Adams on 21 Febbraio, 2020 at 12:29 pm

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval for the first gene therapy for the bleeding disease.

by Nick Paul on 21 Febbraio, 2020 at 11:18 am

Spark Therapeutics co-founder and R&D head Kathy High has left the gene therapy specialist in the wake of its takeover by Roche. The Basel-based Big Pharma talked up its ability to cope with the loss of the R&D chief, pointing to the 450-person team High helped build to back up its confidence.

by Ben Adams on 21 Febbraio, 2020 at 9:03 am

Genfit’s shares were in the red Friday morning after the French biotech announced it was delaying a data readout for its potential blockbuster fatty liver hopeful elafibranor.

by Jonathan Smith on 21 Febbraio, 2020 at 8:13 am

The Heidelberg-based startup Velabs Therapeutics aims to make anti-aging drugs that selectively destroy ‘aged’ cells in the body. Mission: To develop antibody drugs using microfluidics technology that can kill old or ‘senescent’ cells, which have been linked to the development of age-related conditions such as cardiovascular disease, dementia, and macular degeneration. While there are various treatments available to tackle age-related diseases, they often can only treat the symptoms of the condition, and fail to address one of the main risk factors: the aging process.  To meet this challenge, Velabs Therapeutics is one of several biotechs aiming to develop treatments that can slow aging.  “Right now there is nothing really effective in clinical use, apart from the typical cosmetic measures,” Christoph Antz, CEO of Velabs Therapeutics, told me. “There may be some hormone-based treatments on offer, but this is always questionable.”  Velabs Therapeutics is developing antibodies to destroy a specific type of cell called senescent cells. These cells occur in both young and old people when healthy cells cease being able to reproduce, and protect us from tumors by stopping potentially cancerous cell damage from propagating.   However, senescent cells build up more in the tissues of older people and are thought to be one of the so-called hallmarks of aging. The post This Startup is Developing Anti-Aging Antibodies appeared first on Labiotech.eu.

on 21 Febbraio, 2020 at 12:00 am

The company indicated then that it still believes all four HHS PrEP patents are invalid and should not have been granted.

on 21 Febbraio, 2020 at 12:00 am

The trial shows that the drug decreased the mortality rate of stroke from 19% to 11%.

on 21 Febbraio, 2020 at 12:00 am

The target action date is August 21, 2020.

on 21 Febbraio, 2020 at 12:00 am

Katherine High, the longtime head of research and development at Spark Therapeutics, is stepping down from the company as it prepares to be absorbed by Swiss pharma giant Roche.

on 21 Febbraio, 2020 at 12:00 am

The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.

on 21 Febbraio, 2020 at 12:00 am

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

on 21 Febbraio, 2020 at 12:00 am

Biopharma and life sciences companies strengthen their leadership teams and board with this week's Movers & Shakers.

on 21 Febbraio, 2020 at 12:00 am

First, prioritize these criteria according to your own desires and needs. Which aspects of the offer do you most value?

on 21 Febbraio, 2020 at 12:00 am

Before you even begin researching, prioritize which aspects of the job offer are most important to you.

by Kyle Blankenship on 20 Febbraio, 2020 at 9:32 pm

Merck & Co. digital head Scholefield bolts for Marriott; Endo replaces CEO Campanelli; BMS vet Quigley joins Gilead.

by Kristin Jensen on 20 Febbraio, 2020 at 7:45 pm

Set to last 20 years, the contract between Wuxi and an unidentified vaccine maker calls for the Chinese CDMO to build a dedicated production plant. 

by Ned Pagliarulo on 20 Febbraio, 2020 at 5:00 pm

For $50 million upfront, the British pharma will gain access to two T cell therapies Immatics is developing to treat solid tumors. 

by Jacob Bell on 20 Febbraio, 2020 at 4:48 pm

Austedo, a main growth driver for Teva, failed two late-stage studies that were supposed to get the drug approved as a treatment for tics in young patients with Tourette's.

by Ned Pagliarulo on 20 Febbraio, 2020 at 4:30 pm

After a Phase 3 brain cancer study missed its goal last fall, Tocagen laid off two-thirds of its workforce and began evaluating its options.

by Arlene Weintraub on 20 Febbraio, 2020 at 2:11 pm

Scientists at the Hubrecht Institute in the Netherlands used base editing, an approach to CRISPR that doesn’t involve cutting DNA, to correct a gene mutation that causes cystic fibrosis (CF). They believe the study, which they performed in stem cells from CF patients, provides evidence that a disease-causing mutation in the gene CFTR could be corrected without damaging healthy parts of the genome.

by Nick Paul on 20 Febbraio, 2020 at 1:08 pm

Everest Medicines has named Eli Lilly veteran Kerry Blanchard as its CEO. Blanchard takes up the top job at the Shanghai-based biopharma company on the back of a career built around a 17-year spell at Lilly.